Liu Yang, Kong Liang, Yu Yang, Zang Juan, Zhang Lu, Guo Rui-Bo, Li Shu-Tong, Cheng Lan, Li Xue-Tao, Chen You-Qiang
School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 116600, People's Republic of China.
Shenyang Key Laboratory of Chinese Medicine Targeted Delivery Key Laboratory, Shenyang, 110847, People's Republic of China.
Int J Nanomedicine. 2025 Jan 7;20:215-238. doi: 10.2147/IJN.S470219. eCollection 2025.
Ovarian cancer is difficult to detect in its early stages, and it has a high potential for invasion and metastasis, along with a high rate of recurrence. These factors contribute to the poor prognosis and reduced survival times for patients with this disease. The effectiveness of conventional chemoradiotherapy remains limited. Nano-particles, as a novel drug delivery system, have significant potential for improving therapeutic efficacy and overcoming these challenges.
According to the high expression level of matrix metalloproteinase-2 (MMP-2) in the tumor microenvironment, MMP-2 responsive nano-particles (PVGLIG-MTX-D/T-NMs) containing docetaxel and triptolide were prepared by the thin-film dispersion method. The synergistic effect between docetaxel and triptolide was systematically investigated, the ratio of the two drugs was optimized, and the physicochemical properties of the nano-particles and their ability to inhibit ovarian cancer cell growth and metastasis were evaluated in vitro and in vivo.
PVGLIG-MTX-D/T-NMs enhanced the targeting, stability, and bioavailability of the drug, while reducing the dose and toxicity. In addition, by regulating the expression levels of E-Cadherin, N-Cadherin, matrix metalloproteinases (MMPs), hypoxia-inducible factor 1-alpha (HIF-1α), and vascular endothelial growth factor (VEGF), it exhibited an inhibitory effect on epithelial-mesenchymal transformation (EMT) and tumor cell angiogenesis, and effectively inhibited the invasion and metastasis of ovarian cancer cells.
PVGLIG-MTX-D/T-NMs achieved passive targeting of tumor sites by enhancing permeability and retention (EPR) effects. Subsequently, the uptake of the drug by tumor cells was enhanced by MMP-2 responsiveness and the modification of methotrexate targeting ligands. By regulating the expression levels of invasion- and metastasis-related proteins in tumor tissues, the nano-particles affected the EMT process, inhibited tumor angiogenesis, and suppressed the malignant potential of invasion and metastasis in ovarian cancer. These findings provided a new direction for further exploration of tumor-targeted therapy.
卵巢癌在早期阶段难以检测,具有较高的侵袭和转移潜力,且复发率高。这些因素导致该疾病患者预后不良,生存时间缩短。传统放化疗的效果仍然有限。纳米颗粒作为一种新型药物递送系统,在提高治疗效果和克服这些挑战方面具有巨大潜力。
根据肿瘤微环境中基质金属蛋白酶-2(MMP-2)的高表达水平,采用薄膜分散法制备了负载多西他赛和雷公藤内酯醇的MMP-2响应性纳米颗粒(PVGLIG-MTX-D/T-NMs)。系统研究了多西他赛和雷公藤内酯醇之间的协同作用,优化了两种药物的比例,并在体外和体内评估了纳米颗粒的理化性质及其抑制卵巢癌细胞生长和转移的能力。
PVGLIG-MTX-D/T-NMs增强了药物的靶向性、稳定性和生物利用度,同时降低了剂量和毒性。此外,通过调节E-钙黏蛋白、N-钙黏蛋白、基质金属蛋白酶(MMPs)、缺氧诱导因子1-α(HIF-1α)和血管内皮生长因子(VEGF)的表达水平,它对上皮-间质转化(EMT)和肿瘤细胞血管生成具有抑制作用,并有效抑制卵巢癌细胞的侵袭和转移。
PVGLIG-MTX-D/T-NMs通过增强渗透滞留(EPR)效应实现了对肿瘤部位的被动靶向。随后,通过MMP-2响应性和甲氨蝶呤靶向配体的修饰增强了肿瘤细胞对药物的摄取。通过调节肿瘤组织中侵袭和转移相关蛋白的表达水平,纳米颗粒影响EMT过程,抑制肿瘤血管生成,并抑制卵巢癌侵袭和转移的恶性潜能。这些发现为进一步探索肿瘤靶向治疗提供了新方向。